Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.

LUND, Sweden, June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 ...

Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified. Post-hoc analyses indicated the 300-mg monthly maintenance ...

Please provide your email address to receive an email when new articles are posted on . New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs.

For adults with high-risk opioid use disorder (OUD), both 100-mg or 300-mg monthly maintenance injections of extended-release buprenorphine improved opioid abstinence, but the higher dose seemed to ...

More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

While a recent Canadian study was unable to demonstrate superiority of extended-release injectable buprenorphine (ER-IBUP) taken weekly or monthly over daily dosing for people with opioid use disorder ...

About The Study: In this multicenter randomized clinical trial, rapid induction had higher retention than standard induction overall and in patients who tested positive for fentanyl through ...

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...